Background: In advanced gastric cancer, doublet regimen with cisplatin and fluoropyrimidine is considered as a 1
) and 5-fluorouracil ("DCF regimen") every 3 weeks has been shown to improve efficacy of 1 st -line trt in a phase III trial. However, this regimen was associated with more frequent grade 3-4 toxicities, such as diarrhea, neutropenia and complicated neutropenia (febrile neutropenia or neutropenic infection). Oxaliplatin has been shown to be more tolerable than cisplatin with the same efficacy. The addition of docetaxel at 50 mg/m 2 every 2 weeks to the FOLFOX (TFOX regimen) showed to be active and tolerable in phase II studies and less toxic as compared DCF regimen. The aim of this current phase III study is to compare FOLFOX to TFOX in 1 st line trt of advanced gastric cancer. Clinical, Halozyme Therapeutics, San Diego, CA, USA, 10 Division of HematologyOncology, Beth Israel Deaconess Medical Center, Boston, MA, USA Background: Poor outcome in PDA is associated with stromal hyaluronan (HA) accumulation, which may compromise treatment access. In animal models, PEGPH20 degrades tumor HA. Key data from a Phase 2 study showed that PEGPH20 plus chemotherapy improved efficacy over chemotherapy alone in tumors retrospectively identified to accumulate HA ("HA-High"). The objectives of this Phase 3 study are to compare efficacy and safety of standard-dose nab-paclitaxel (NAB) and gemcitabine (GEM) combined with PEGPH20 or placebo in patients with HA-High, previously untreated, Stage IV PDA. Primary endpoints are progression-free survival (PFS) and overall survival (OS). Secondary endpoints are objective response rate, duration of response, and safety. Trial design: 420 patients 18 years with untreated HA-High metastatic PDA, ECOG PS 0-1 are randomized (stratified by North America/Europe/Other) 2:1 to NAB 125 mg/m 2 þ GEM 1000 mg/m 2 þ PEGPH20 3.0 lg/kg or to NAB þ GEM þ placebo, respectively. Patients with HA-High tumors are prospectively identified by the codeveloped VENTANA HA RxDx Assay, which identifies HA in the extracellular matrix. HA-High status (indicating patients who may achieve clinical benefit) was determined by Halozyme to be 50% HA staining based on clinical outcome data from a Phase 2 study. Treatment is provided in 4-week cycles (Wk 1-3, Wk 4 rest) until disease progression, unacceptable toxicity, death, or consent withdrawal. PEGPH20 or placebo is given twice weekly (Cycle 1) then weekly (Cycles 2þ), NAB þ GEM once weekly for all cycles. Dexamethasone is given before and after PEGPH20 to reduce treatment-related musculoskeletal symptoms and enoxaparin is given to minimize thromboembolic events. Tumor response will be assessed by an independent central imaging vendor using RECIST v1.1. Adverse events will be graded per NCI CTCAE v4.03. An independ
